Alkem Labs Ka Bawaal! EU Se Approval + ₹533 Cr India Expansion Ka Plan

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Alkem Labs Ka Bawaal! EU Se Approval + ₹533 Cr India Expansion Ka Plan
Overview

Boss Log, Alkem Laboratories ne ekdum se do bade steps liye hain! Pehle toh unke Daman plant ko EU GMP approval mil gaya hai, matlab ab Europe mein export ka raasta saaf. Aur dusra, company India mein ₹533 crore ka tagda expansion karne wali hai Ujjain mein. Ye sab unke acche Q3 results ke baad hua hai.

Global Access Aur India Mein Dum!

Alkem Labs apna business badhane ke liye ek dum mast strategy par kaam kar raha hai. Recently, unke Daman wale plant ko European Union Good Manufacturing Practices (GMP) ka approval mil gaya hai. Ye certification teen saal ke liye valid hai aur Malta Medicines Authority ne diya hai. Iska matlab hai ki Alkem ab Europe ke strict quality standards ko follow karta hai, jo ki export business, khaas kar regulated European markets mein, badhane ke liye bohot zaroori hai. Pehle is plant mein kuch observations the, jinko company ne ab theek kar diya hai.

Ujjain Mein ₹533 Crore Ka Naya Plant!

Aur yehi nahi, company ne India mein bhi apna production capacity badhane ka plan banaya hai. Alkem ke board ne ₹533 crore tak ka paisa approve kiya hai Madhya Pradesh ke Ujjain mein ek naya greenfield plant banane ke liye. Iske liye company ne around 30 acres zameen bhi kharid li hai. Is move ka goal hai domestic demand ko pura karna.

Q3 Results Bhi Bade Acche The!

Ye dono bade steps unke December quarter (FY25) ke zabardast financial results ke baad aaye hain. Alkem ka Net Profit 5% year-on-year badh kar ₹626 crore ho gaya hai. Revenue 1.5% badh kar ₹3,374 crore raha. EBITDA bhi 7.4% badh kar ₹759 crore ho gaya, aur EBITDA margins 22.5% tak pahunch gaye, jo company ke 9-month guidance se bhi upar tha.

Market Reaction Thoda Muted?

Itni achi news hone ke bawajood, Alkem ke share price mein bas thoda sa hi rise dekha gaya. Lagta hai investors Ujjain wale plant ke liye required huge capital investment ko lekar thoda cautious hain, aur US market mein chal rahe price pressure ko bhi dekh rahe hain.

Valuation Aur Competitors Ko Bhi Dekhte Hain

Agar Valuation ki baat karein, toh Alkem ka trailing twelve-month P/E ratio around 22.1 se 28.79 ke beech hai (March 2026 tak). Ye Dr. Reddy's Laboratories (P/E around 18.36-19.61) aur Cipla (P/E around 20.5-23.93) ke competitors se compare kare toh theek hai, lekin Sun Pharmaceutical Industries (P/E around 34.19 to 40.13) se kam hai. Alkem ki market cap lagbhag ₹661.19 billion thi.

Industry Ka Scene Aur Risks

Indian pharma sector mein domestic demand toh acchi hai, lekin US generics market mein price erosion ek bada issue hai. Alkem ki 19.1% sales US se aati hai, toh wahan ka pressure profit margins par asar daal sakta hai. Ujjain wale ₹533 crore ke investment mein bhi execution risks hain, jinko manage karna padega.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.